Buy Nurix (NRIX): Bexobrutideg Pivotal Runway and Multiple Near-Term Catalysts
Nurix Therapeutics is trading at $16.24 after a constructive corporate update and strong Phase 1 data for its BTK degrader bexobrutideg. With DAYBreak pivotal enrollment underway, a planned Phase 3 start by mid-2026, and a healthy cash position of $540.7M, we rate NRIX a Strong Buy. Our trade plan targets $24.00 over a 180 trading day horizon with …